This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2016, there were 556,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 609,500 incident cases by 2025.
• Incident cases are highest in Asia, and lowest in the Oceania region. Roche’s Avastin, Mylan’s biosimilar bevacizumab, and Amgen’s Mvasi, which target vascular endothelial growth factor; Novartis’s Hycamtin, a topoisomerase I inhibitor; Pinnacle’s Photofrin, a photodynamic therapy; and Merck’s Keytruda, an anti-PD-1 antibody, are the marketed drugs available for cervical cancer. The majority of marketed drugs are administered via the intravenous route.
• The majority of industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with only two drugs in Phase III.
• Therapies in mid-to-late-stage development for cervical cancer focus on a wide variety of targets. The majority of pipeline drugs in the cervical cancer space are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, and intranasal formulations.
• High impact upcoming events for drugs in the cervical cancer space comprise topline Phase III trial results for cemiplimab. The overall likelihood of approval of a Phase I cervical cancer asset is 10%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
• There have been 11 licensing and asset acquisition deals involving cervical cancer drugs during 2013–18. The $727.5m license agreement between Inovio and MedImmune for the exclusive rights to develop and market Inovio’s INO-3112 was the largest deal.
• The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94.7% of trials in Phase I–II, and only 5.3% in Phase III–IV.
• The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
• Clinical trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca has the highest number of ongoing clinical trials for cervical cancer, with 13 trials.
• AstraZeneca leads industry sponsors with the highest number of clinical trials for cervical cancer, followed by Roche.